BOrrelia BUrgdorferi IN Children and Adolescents

NCT05856812 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 962

Last updated 2024-11-26

No results posted yet for this study

Summary

The aim of this study is to assess B. burgdorferi antibodies in children and adolescents in north-western Switzerland and neighbouring countries ("Triregio") treated at the University Children's Hospital Basel to define age-dependent B. burgdorferi seroprevalence rates.

Conditions

  • B. Burgdorferi Infection

Sponsors & Collaborators

  • University Children's Hospital Basel

    lead OTHER

Principal Investigators

  • Ulrich Heininger, Prof. · University Childrens Hospital

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2024-02-06
Completion
2024-02-06

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856812 on ClinicalTrials.gov